Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 2/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31622840 | 0.89 | ALDH1A1 (0.46) | ALDH1A1KDM4ESMN1; SMN2CES2MAPT | |
| SCHEMBL16403508 | 0.89 | ALDH1A1 (0.46) | ALDH1A1KDM4ESMN1; SMN2CES2MAPT | |
| SCHEMBL17894535 | 0.80 | ALDH1A1 (0.55) | ALDH1A1KDM4ESMN1; SMN2MAPTATM | |
| SCHEMBL17894524 | 0.78 | MAPT (0.56) | ALDH1A1KDM4ESMN1; SMN2MAPTATM | |
| SCHEMBL18002126 | 0.77 | KDM4E (0.51) | ALDH1A1KDM4ESMN1; SMN2MAPTCYP2D6 | |
| SCHEMBL18002236 | 0.74 | PPARG (0.40) | MAPTCYP3A4CYP2D6 | |
| SCHEMBL6864791 | 0.74 | CES2 (0.47) | CES2SRD5A2CYP3A4CYP2D6 | |
| SCHEMBL18003066 | 0.74 | CYP2A6 (0.42) | SRD5A2 | |
| SCHEMBL18001839 | 0.70 | KIF11 (0.50) | ALDH1A1CES2SRD5A2CYP3A4CYP2D6 | |
| SCHEMBL10499962 | 0.69 | ALDH1A1 (0.61) | ALDH1A1KDM4ESMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4219477-A1 | CYANOTRIAZOLE COMPOUNDS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2023-08-02 | — | — | EP | disclosed |
| US-10626095-B2 | Cyanotriazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-04-21 | — | — | US | disclosed |
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2016-08-11 | — | — | US | disclosed |
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2016-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10626095-B2 | Cyanotriazole compounds | CS, PC, ACAT1 | ALDH1A1 1611/4885KDM4E 2681/4885SMN1; SMN2 3834/4885 |
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | CS, PC, ACAT1 | ALDH1A1 1611/4885KDM4E 2681/4885SMN1; SMN2 3834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.